search
Back to results

Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.

Primary Purpose

Thoracic Outlet Syndrome, Whiplash Injuries

Status
Not yet recruiting
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
IncobotulinumtoxinA 100 UNT
Sponsored by
King, David, MD
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thoracic Outlet Syndrome

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Patient must have been diagnosed with a muscle strain to the lateral neck muscles following a car accident and there must be the following clinical signs of TOS: pain in the proper distribution, weakened grip, shoulder elevation on the appropriate side and numbness or tingling in the arm or fingers;

    • Patient must have no signs suggesting a radiculopathy that could account for similar symptoms;
    • Patient must have a PDQ >70, i.e. in the moderate to very severe disability range;
    • Patient must experience symptoms for longer than 3 months;
    • Patient must have had the accident leading to whiplash within the last 3 years;
    • Patient must be 18 years of age or older;
    • Patient must be eligible and agreeable to treatment with BoNT-A;
    • Patient must be toxin-naïve for the treatment of the cervical region, or have undergone a six months washout period;
    • Patient must be English speaking;
    • Patient must be able to provide informed consent.

Exclusion Criteria:

  • • Patient unable or unwilling to complete the necessary assessment tasks;

    • Patient with hypersensitivity to botulinum neurotoxin type A or to any of the excipients, generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome), or infection or inflammation at the proposed injection site(s);
    • Patient who requires physiotherapy and/or massage therapy;
    • Patient for whom concomitant medications are not controlled at study start and/or may require change/adjustment during the study;
    • Patient who had surgery which may interfere with the study;
    • Women who are pregnant or nursing, or women in age of reproduction not using a contraceptive method;
    • Patient in active litigation.

Sites / Locations

  • Private Office

Outcomes

Primary Outcome Measures

Change from baseline in pain disability as assessed using the PDQ at Week 4.
PDQ before and after treatment. Pain Disability Questionnaire (Guides to the Evaluation of Permanent Impairment, Sixth Edition. 0= No pain related impairment 1-70= Mild pain related impairment 71-100=Moderate pain related impairment 101-130= Severe pain related impairment 131-150= Extreme pain related impairment

Secondary Outcome Measures

Shoulder Elevation
Change from baseline in shoulder elevation as assessed by measurement on photograph (clavicular angle) at Weeks 4, 12 and 16;
Grip Strength
3. Change from baseline in grip strength as assessed using a dynamometer at Weeks 4, 12 and 16;
Pinch Test
4. Change from baseline in fine motor test (pinch test) at Weeks 4, 12 and 16;

Full Information

First Posted
July 27, 2022
Last Updated
September 9, 2022
Sponsor
King, David, MD
Collaborators
MERZ PHARMA
search

1. Study Identification

Unique Protocol Identification Number
NCT05536570
Brief Title
Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.
Official Title
Management of Functional Thoracic Outlet Syndrome (TOS - Whiplash) With IncobotulinumtoxinA Injections
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 15, 2022 (Anticipated)
Primary Completion Date
April 15, 2023 (Anticipated)
Study Completion Date
June 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King, David, MD
Collaborators
MERZ PHARMA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Whiplash injuries following car accident are common, it has been reported to affect 83% of individuals injured in traffic collisions (Yadla S, 2007). The condition is caused by a rapid acceleration followed immediately by a rapid deceleration of the neck and head. The annual North American incidence rate is estimated to be 600 per 100,000 people (Holm LW, 2008). The condition is costly for society and disabling/painful for the patients. Depending on the collision type, the biomechanics of muscles will be affected differently and consequently the clinical presentation will vary. T-bone type of car collisions (when the front of one vehicle strikes the side of another) may induce thoracic outlet syndrome (TOS) following compression on the nerve and artery bundle by the scalene muscles (lateral stabilizers of the neck). An appropriate and detailed examination of the patient is necessary to identify the cause of the resulting pain and disability. Once a functional thoracic outlet syndrome is identified the proposal is to treat this with botulinum toxin.
Detailed Description
TOS symptoms will typical emerge within 24-48 hours following the accident. The duration will depend on the level of severity of the muscle damage. If the severity is a grade 1 (mild damage to individual muscle fibers), symptoms may last up to 3 weeks. If the severity is a grade 2 (more extensive damage with more muscle fibers involved/no complete rupture), symptoms may last up to 3 months. However, in many cases, due to muscle swelling and consequently compression of the nerve plexus, a persistent reflex spasm of muscle develops. A potentially effective treatment strategy, in patients presenting TOS associated clinical symptoms in the proper distribution, is to relax the scalene muscles that surround the nerve plexus. Botulinum toxin, such as incobotulinumtoxinA (XEOMIN, Merz herapeutics), have been shown to be effective and safe in relaxing these muscles in conditions like spasticity, blepharospasm and cervical dystonia (Kanovský P, 2009; Benecke R, 2005; Roggenkämper P, 2005). It is hypothesised that a subtype of whiplash defined as functional TOS could be improved with incobotulinumtoxinA injections into the medial scalene muscle. IncobotulinumtoxinA when injected into the medial scalene is expected to induce muscle relaxation which leads to nerve plexus decompression. The effect is anticipated to last approximately 3 months, which is the duration of effect of botulinum toxins type A. A similar effect can be induced using a local anaesthetic, such xylocaine, since it has a similar mechanism of action, but his effect should be short lived.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thoracic Outlet Syndrome, Whiplash Injuries

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
Patients who have neck pain and arm paresthesia following a side-on collision
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
IncobotulinumtoxinA 100 UNT
Intervention Description
Scalene injection
Primary Outcome Measure Information:
Title
Change from baseline in pain disability as assessed using the PDQ at Week 4.
Description
PDQ before and after treatment. Pain Disability Questionnaire (Guides to the Evaluation of Permanent Impairment, Sixth Edition. 0= No pain related impairment 1-70= Mild pain related impairment 71-100=Moderate pain related impairment 101-130= Severe pain related impairment 131-150= Extreme pain related impairment
Time Frame
week 4
Secondary Outcome Measure Information:
Title
Shoulder Elevation
Description
Change from baseline in shoulder elevation as assessed by measurement on photograph (clavicular angle) at Weeks 4, 12 and 16;
Time Frame
week 4
Title
Grip Strength
Description
3. Change from baseline in grip strength as assessed using a dynamometer at Weeks 4, 12 and 16;
Time Frame
Week 4
Title
Pinch Test
Description
4. Change from baseline in fine motor test (pinch test) at Weeks 4, 12 and 16;
Time Frame
WFeek 4

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Patient must have been diagnosed with a muscle strain to the lateral neck muscles following a car accident and there must be the following clinical signs of TOS: pain in the proper distribution, weakened grip, shoulder elevation on the appropriate side and numbness or tingling in the arm or fingers; Patient must have no signs suggesting a radiculopathy that could account for similar symptoms; Patient must have a PDQ >70, i.e. in the moderate to very severe disability range; Patient must experience symptoms for longer than 3 months; Patient must have had the accident leading to whiplash within the last 3 years; Patient must be 18 years of age or older; Patient must be eligible and agreeable to treatment with BoNT-A; Patient must be toxin-naïve for the treatment of the cervical region, or have undergone a six months washout period; Patient must be English speaking; Patient must be able to provide informed consent. Exclusion Criteria: • Patient unable or unwilling to complete the necessary assessment tasks; Patient with hypersensitivity to botulinum neurotoxin type A or to any of the excipients, generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome), or infection or inflammation at the proposed injection site(s); Patient who requires physiotherapy and/or massage therapy; Patient for whom concomitant medications are not controlled at study start and/or may require change/adjustment during the study; Patient who had surgery which may interfere with the study; Women who are pregnant or nursing, or women in age of reproduction not using a contraceptive method; Patient in active litigation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David B King, BSc, MD
Phone
902 425 7344
Email
david.larkspur@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Debbie Cavicchi, BA
Phone
902 425 7344
Email
dking@davidbking.ca
Facility Information:
Facility Name
Private Office
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3P 1M3
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David B King, BSc, MD
Phone
902 425 7344
Email
david.larkspur@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.

We'll reach out to this number within 24 hrs